Nachrichten zur Eli Lilly & Co Aktie

LLY Down as Patients Regain Weight After Stopping Zepbound

Full results from a late-stage study show that patients who stopped taking Eli Lillys (LLY) weight-loss drug for over a…

AKTIE IM FOKUS: Studiendaten belasten Pharma-Schwergewicht Eli Lilly

NEW YORK (dpa-AFX) - Aktuelle Daten zum Abnehmmittel Zepbound (Tirzepatide) haben den in diesem Jahr bislang…

Eli Lilly sell-off shows investors are misinterpreting a study that we view as positive

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

The sell-off of Eli Lilly stock shows investors are misinterpreting a study that we view as a positive

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

Novo-Nordisk-Konkurrent Eli Lilly: Studiendaten zu Abnehmmittel setzen Aktie unter Druck

Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…

Novo-Nordisk-Konkurrent Eli Lilly: Studiendaten zu Abnehmmittel setzen Aktie unter Druck

Die Aktie des Pharmakonzerns Eli Lilly muss am heutigen Montag kräftig Federn lassen. Mehr als drei Prozent geht es bei…

Patients regain weight after stopping Eli Lillys Zepbound, study says

The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.…

Stocks making the biggest moves midday: Macys, Cigna Group, Eli Lilly, Paramount and more

These are the stocks posting the largest moves in midday trading.…

AKTIE IM FOKUS: Eli Lilly sehr schwach nach gutem Lauf und Studiendaten

NEW YORK (dpa-AFX Broker) - Die Aktien von Eli Lilly sind am Montag nach einem…

Eli Lilly obesity drug patients regained weight after ending treatment: study

Individuals using Eli Lilly and Co (NYSE:LLY)’s obesity drug Zepbound (tirzepatide) regained weight after they stopped using the treatment, according…

Eli Lilly slips as weight loss drugs effect reverses after therapy

…

Eli Lilly slumps after disappointing Zepbound weight-loss-drug trial

Zepbound, which Eli Lilly had hoped would offset the slide in Trulicity sales, had mixed results in a major clinical…

ALLR: Stenoparib Clinical Update

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…

Should You Buy Eli Lilly Stock Now or Wait for a Dip? @themotleyfool #stocks $LLY

Eli Lillys P/E ratio of more than 100 looks steep, but the company is on the cusp of further huge…

Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?

Theres no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has…

Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks

Shares in Eli Lilly are up around 60% year-to-date, while Novo Nordisk has gained around 50%. Should investors buy either…

Eli Lilly weight loss drug Zepbound now available at pharmacies as rival Wegovy faces shortages

Eli Lillys drug serves as an alternative to rival obesity drugs such as Wegovy that are still facing supply issues.…

POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?

SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Stakeholder rights law firm Johnson Fistel, LLP has launched an…

Eli Lillys weight loss drug Zepbound is now available at US pharmacies

Eli Lilly and Co (NYSE:LLY) announced that its weight loss drug Zepbound is now available at pharmacies in the US,…

Eli Lilly’s New Weight-Loss Drug Now on Sale to Rival Hard-to-Find Wegovy

Eli Lilly & Co.’s new weight-loss drug Zepbound is now available at US pharmacies, offering an alternative to rival medications…

Eli Lillys obesity drug now available in U.S. pharmacies

Eli Lillys recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured…

Eli Lillys obesity drug now available in U.S. pharmacies By Reuters

Eli Lillys obesity drug now available in U.S. pharmacies…

: Eli Lilly’s new obesity drug Zepbound added to major PBM formularies as it hits pharmacy shelves

Eli Lilly & Co. LLY said Tuesday its new obesity drug Zepbound has been added to a major pharmacy benefit…

How every Club stock performed over the past 10 Decembers, a historically strong month

Over the past decade, December been especially kind to Broadcom (AVGO) and Eli Lilly (LLY).…

Pro Research: Wall Street takes on Eli Lillys prospects By Investing.com

Pro Research: Wall Street takes on Eli Lillys prospects…

Amphastar, Stock Of The Day, Breaks Out As It Sees Upside From Eli Lilly Deal

Amphastar is IBD Stock Of The Day as the biotech stock revs up marketing of Baqsimi, a drug purchased this…

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15 By Reuters

Eli Lilly extends tender offer to buy Point Biopharma to Dec. 15…

Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?

Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…

Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk? @themotleyfool #stocks $LLY $NVO

Both of these stocks have been big winners this year. But one could be better positioned to extend that winning…

US FDA gives second approval to Eli Lillys drug for type of blood cancer

Eli Lilly said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca,…

Why Pfizers latest stumble in the obesity market is a boon for Eli Lilly

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and thats good news for…

Why investors should stick with Eli Lilly

The Investing Club holds its Morning Meeting every weekday at 10:20 a.m. ET.…

1 Underrated Reason to Buy Eli Lilly Stock @themotleyfool #stocks $LLY

Eli Lilly has a well-rounded business that can be a good fit for all types of investors.…

Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low

Investors’ have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight…

Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly

…

LEXX: GLP-1s’ Sweet Opportunity

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with…

Here are Thursdays biggest analyst calls: Nvidia, Apple, Eli Lilly, Salesforce, Snowflake, Snap, Pinterest & more

Here are the biggest calls on Wall Street on Thursday.…

Eli Lillys Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the…

Eli Lillys Weight-Management Drug Outperformed Ozempic. Is It Time to Buy? @themotleyfool #stocks $LLY $NVO

Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the…

Cramer says Eli Lilly is the only drug stock that’s working as it differentiates itself among competitors

The Investing Club releases the Homestretch weekday audio feature in time for the last hour of trading on Wall Street.…

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

…

Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego

The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and…

3 Large Drug Stocks That Have Outperformed Industry YTD

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.…

: Eli Lilly’s Mounjaro three times more effective than Ozempic for weight loss, real-world study finds

Eli Lillys Mounjaro is significantly more effective than Novo Nordisks Ozempic in producing weight loss, a real-world study found…

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says

Patients on Eli Lillys Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to…

Synthetic Hormones Market Analysis Report 2023-2033, Featuring Profiles of Eli Lilly, Pfizer, Ferring, Merck, Novo Nordisk, Bayer, Novartis and More

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Synthetic Hormones Market: Focus on Product Type, Application, Route…

dpa-AFX ProFeed